BusinessFrance

Bioamber produces bio-based 1,4-butanediol on industrial scale

28.03.2012 - Bioamber Inc. is one step closer to the environmental summit. The company's goal is to establish sustainable, "green" chemistry on an industrial scale.

The French/US enterprise has now scaled up its hydrogenation catalyst technology for converting biologically produced succinic acid into 1,4-butanediol (1,4-BDO), tetrahydrofuran (THF) and gamma-butyrolactone (GBL). These bulk chemicals are needed for making polyesters, polyurethanes, spandex and biodegradable plastics. The global addressable market for these products exceeds $4bn, according to BioAmber, with an annual market for 1,4-BDO alone of 1.3m tons. Bio-succinate has being produced since 2010 near Reims in a huge 350,000L fermenter from corn. Other production sites are planned for Canada (Sarnia, Ontario) and Thailand. According to Chief Technology Officer Jim Millis, Bioamber "is developing an integrated plant engineering design that combines the production of bio-succinic acid and bio-based 1,4-BDO on a single site". So far bio-succinate comes from Bioamber S.A.S's factory in France (Banzancourt/Pomacle). The endeavour to refine succinate into 1,4-BDO was undertaken together with DuPont (USA) which is one of the world's leading commercial catalyst suppliers. After successfully having established industrial C4-chemistry based on renewable resources, Bioamber is in the process of producing a C6-molecule (adipic acid), also in a sustainable manner. However, industrial production is not anticipated to start before 2015.

FundingEU

17.04.2014 The European Parliament has given green light to the second Innovative Medicines Initiative with the aim to advance pharmacological research and development, particularly in areas of unmet medical need.

BusinessGermanyFrance

15.04.2014 German flavour and scent specialist Symrise has announced its plans to acquire French pet-food ingredients maker Diana Group for €1.3bn.

BioeconomySpain

14.04.2014 Spanish Neol Biosolutions and the Center for Second Generation Biofuels are starting a partnership to scale-up Neol's waste-to-oil technology.

EvidenceUKSwitzerland

11.04.2014 There is no evidence that neuraminidase inhibitors Tamiflu and Relenza prevent complications of influenza or reduce hospital admissions. In addition, it is unclear whether they can stop the spread of influenza in case of outbreaks, says a report by the Cochrane Collaboration.

BusinessSwitzerlandSpain

09.04.2014 Roche is extending its involvement in the area of point-of-care diagnostics by taking over US company Iquum. In the field of epigenetics, the Swiss pharma company has started a cooperation with the Spanish company Oryzon.

Status ReportSwitzerland

08.04.2014 The Swiss Biotech Report 2014 presented in Zurich sees an encouraging upturn in the country's biotech scene. However, the acceptance of the mass immigration initiative poses a significant threat.

NanobiotechnologyItaly

07.04.2014 Scientists from the University of Udine have designed, produced and tested a prototype for a "DNA origami" nanorobot that can potentially deliver biological activators in-vivo.

EpidemicEUFranceGermanyItaly

02.04.2014 As the Ebola epidemic in Guinea worsens, Europe is deploying the specialists of EMLab to provide diagnostics at the focus of the outbreak.

BioeconomyFranceEU

01.04.2014 The European Commission has approved a French state package aid worth €43m for green chemistry project IEED.

MonitoringEU

27.03.2014 In Europe, bacterial resistance to prevalent antimicrobials is common, while multi-resistance remains low, EFSA and ECDC now report.

Events

All Events

Partner-Events

München

BioVaria 2014

Frankfurt am Main

7th DVFA Life Science Conference

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • PHARMING (NL)0.53 EUR12.8%
  • BAVARIAN NORDIC (D)14.56 EUR10.3%
  • NICOX (F)2.44 EUR7.5%

FLOP

  • XENETIC BIOSCIENCES (UK)6.00 GBP-14.3%
  • GENFIT (F)22.42 EUR-8.1%
  • DEINOVE (F)12.96 EUR-5.3%

TOP

  • WILEX (D)0.92 EUR61.4%
  • CO.DON (D)3.30 EUR61.0%
  • BIOTECH PHARMACON (N)17.50 NOK59.8%

FLOP

  • CYTOS (CH)0.17 CHF-93.9%
  • BIONOR PHARMA (N)2.11 NOK-47.6%
  • GW PHARMACEUTICALS (UK)219.25 GBP-40.4%

TOP

  • SILENCE THERAPEUTICS (UK)256.00 GBP6221.0%
  • IXICO (UK)71.50 GBP810.8%
  • PHARMING (NL)0.53 EUR783.3%

FLOP

  • CYTOS (CH)0.17 CHF-95.8%
  • EVOCUTIS (UK)0.22 GBP-92.5%
  • AGENNIX (D)0.04 EUR-77.8%

No liability assumed, Date: 18.04.2014